Armata opens manufacturing facility in Los Angeles

Armata Pharmaceuticals Inc. (NYSE American: ARMP) announced the formal commissioning of its cGMP manufacturing facility in Los Angeles, California. The company notified the U.S. Food and Drug Administration that production has commenced and completed full production runs without issues.

The 56,000-square-foot facility includes 10,000 square feet of cGMP clean rooms, an automated fill and finish suite, quality control laboratories, research and development laboratories, and administrative space. The facility will manufacture the company's bacteriophage therapeutics to support clinical trials and potential commercial production.

"The full commissioning of our state-of-the-art manufacturing facility in Los Angeles represents a key milestone for Armata, ensuring that we are operationally ready to initiate pivotal studies of our phage-based therapeutics," stated Dr. Deborah Birx, Chief Executive Officer of Armata.

The facility will support the company's clinical programs, including the planned advancement of AP-SA02 into a potential pivotal Phase 3 trial that Armata plans to initiate in 2026, subject to FDA review and feedback. The company also indicated the facility could support future partnering and contract manufacturing opportunities.

Armata is a clinical-stage biotechnology company developing bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. The company is advancing candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.

The information is based on a company press release.

You May Also Be Interested In

• Deere conference call: 2027 orders up mid-single digits from last year)
• LivePerson adjourns stockholder vote on SoundHound AI merger to Sept. 2
• United Airlines expands Denver pilot training center, phase two planned